Beta Bionics has announced that it has partnered with Abbott (NYSE:ABT) to integrate the company’s CGM with its automated insulin delivery system.
The companies plan to combine Abbott’s FreeStyle Libre 3 Plus continuous glucose monitor (CGM) with the Beta Bionics iLet bionic pancreas. According to Beta Bionics, this will make iLet the first available AID system to integrate with Libre 3 Plus in the U.S when it is launched in the fourth quarter of 2024.
Beta Bionics designed its iLet autonomous insulin delivery system to streamline diabetes management. The system, which reduces the burden on patients and physicians, received FDA clearance in May 2023. It uses an adaptive, closed-loop algorithm that initializes with the user’s body weight and requires no additional insulin dosing parameters not any need to manually adjust insulin pump therapy settings and variables. iLet users only input their weight, then the system does the rest.
To find out more, CLICK HERE
